ABCC3 and chronic myelogenous leukemia, BCR-ABL1 positive: An overexpression of ABCC3 was found in patients in blast crisis of chronic myeloid leukemia with disease recurrence [43], and ABCC3 can promote imatinib efflux being responsible for the failure in imatinib-target treatments [44].